 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- Cu-67 SAR-Bombesin / Clarity Pharma
COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer. (Level 1, West Hall; Poster Bd # Q8) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_188;
P1/2
At the time of submission of this abstract, cohort 1 is open for enrollment. Clinical trial information: NCT05633160.
- || Cu-67 SAR-Bombesin / Clarity Pharma
Enrollment open, Metastases: 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) (clinicaltrials.gov) - Jun 18, 2023
P1/2, N=38, Recruiting, Sponsor: Clarity Pharmaceuticals Ltd
Clinical trial information: NCT05633160. Not yet recruiting --> Recruiting
- || Cu-67 SAR-Bombesin / Clarity Pharma
New P1/2 trial, Metastases: 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) (clinicaltrials.gov) - Dec 1, 2022
P1/2, N=38, Not yet recruiting, Sponsor: Clarity Pharmaceuticals Ltd